肺腺癌中SETD7的表达及其临床意义  

Expression of SETD7 in lung adenocarcinoma and its clinical significance

作　　者：陈美茹 姚宁宁 孙润哲 唐洁 刘如丽 于倩倩 孙瑞芳[3] CHEN Mei-ru;YAO Ning-ning;SUN Run-zhe;TANG Jie;LIU Ru-li;YU Qian-qian;SUN Rui-fang(School of Basic Medicine,Shanxi Medical University,Taiyuan 030001,China;Department of Radiotherapy,Shanxi Provincial Cancer Hospital/Shanxi Hospital,Cancer Hospital,Chinese Academy of Medical Sciences/Affiliated Cancer Hospital of Shanxi Medical University,Taiyuan 030013,China;Department of Tumor Biobank,Shanxi Provincial Cancer Hospital/Shanxi Hospital,Cancer Hospital,Chinese Academy of Medical Sciences/Affiliated Cancer Hospital of Shanxi Medical University,Taiyuan 030013,China)

机构地区：[1]山西医科大学基础医学院,太原030001 [2]山西省肿瘤医院/中国医学科学院肿瘤医院山西医院/山西医科大学附属肿瘤医院放射治疗科,太原030013 [3]山西省肿瘤医院/中国医学科学院肿瘤医院山西医院/山西医科大学附属肿瘤医院肿瘤生物样本库,太原030013

出　　处：《临床与实验病理学杂志》2023年第7期816-821,共6页Chinese Journal of Clinical and Experimental Pathology

基　　金：山西省应用基础研究计划(20210302124598)。

摘　　要：目的探讨肺腺癌中SETD7的表达及其临床意义。方法采用qRT-PCR技术检测22例肺腺癌组织和15例癌旁组织中SETD7 mRNA的表达水平;采用免疫组化GTVision法检测162例肺腺癌和57例癌旁组织中SETD7蛋白表达,分析其表达水平与肺腺癌临床病理特征及预后的关系。结果与癌旁组织相比,肺腺癌组织中SETD7 mRNA表达水平明显升高(t=5.212,P<0.0001);同时,SETD7在肺腺癌组织中的蛋白表达水平亦升高,其高表达率(58.6%,95/162)高于癌旁组织(0,0/57)(P<0.001)。SETD7蛋白表达与肺腺癌临床分期(c-TNM分期)相关(P<0.05),与患者性别、年龄、吸烟、饮酒、p-TNM分期、淋巴结转移、复发、EGFR和KRAS突变以及PD-L1表达水平均无关(P>0.05)。Kaplan-Meier生存分析:SETD7蛋白高表达组患者生存率明显低于SETD7低表达组(P<0.0001)。Cox单因素及多因素回归分析显示,SETD7蛋白高表达是影响肺腺癌患者预后的独立危险因素(P<0.001)。结论SETD7在肺腺癌组织中表达明显上调,同时SETD7高表达是影响肺腺癌患者预后的独立危险因素,其可以作为判断肺腺癌患者进展的潜在生物学标志物。Purpose To investigate the expression of SETD7 in lung adenocarcinoma and its clinical prognostic significance.Methods The expression of SETD7 mRNA in 22 cases of lung adenocarcinoma and 15 cases of paracancerous tissues was detected by qRT-PCR,and the expression of SETD7 protein in 162 cases of lung adenocarcinoma and 57 cases of paracancerous tissues was detected by immunohistochemical staining,and the relationship between the expression level of SETD7 and clinicopathological characteristics and prognosis of lung adenocarcinoma patients was analyzed.Results Compared with paracancerous tissues,the mRNA expression levels of SETD7 in lung adenocarcinoma tissues was significantly increased(t=5.212,P<0.0001).At the same time,the expression level of SETD7 protein in lung adenocarcinoma tissue was also increased,and the high expression rate was about 58.6%(95/162),which was higher than that in paracancer tissue(0,0/57)(P<0.001).The expression of SETD7 protein was correlated with clinical stage(c-TNM stage)of lung adenocarcinoma patients,but not with gender,age,smoking,drinking,p-TNM stage,lymph node metastasis,recurrence,EGFR and KRAS mutation and PD-L1 expression level(P>0.05).Kaplan-Meier survival analysis showed that the survival rate of patients with high expression of SETD7 protein was significantly lower than that of patients with low expression of SETD7 protein(P<0.0001).Univariate and multivariate Cox regression analysis revealed that the high expression of SETD7 protein was an independent risk factor for the prognosis of patients with lung adenocarcinoma(P<0.001).Conclusions The expression of SETD7 is significantly up-regulated in lung adenocarcinoma tissues,and the high expression of SETD7 is an independent risk factor affecting the prognosis of lung adenocarcinoma patients,and can be used as a potential biomarker to judge the progression of lung adenocarcinoma patients.

关 键 词：肺肿瘤 腺癌 SETD7 免疫组织化学 预后 

分 类 号：R734.2[医药卫生—肿瘤]